Atwood & Palmer’s Aerie Pharmaceuticals AERI Stock Holding History

Atwood & Palmer’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-200	Closed	-$12K	–	337
2018 Q3	$12K	Hold	200	–	–	﹤0.01%	253
2018 Q2	$14K	Hold	200	–	–	﹤0.01%	247
2018 Q1	$11K	Hold	200	–	–	﹤0.01%	249
2017 Q4	$12K	Hold	200	–	–	﹤0.01%	244
2017 Q3	$10K	Hold	200	–	–	﹤0.01%	255
2017 Q2	$11K	Buy	+200	New	+$9.31K	﹤0.01%	255

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Atwood & Palmer's AERI Position: Q4 2018 in Review

Atwood & Palmer sold out of Aerie Pharmaceuticals (AERI) in Q4 2018, closing a stake of 200 shares — an estimated $12K sold.

Atwood & Palmer first reported a position in AERI in Q2 2017 and held it in 6 quarters. The position peaked at $14K in Q2 2018. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

Atwood & Palmer reported no remaining Aerie Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Atwood & Palmer sold 200 Aerie Pharmaceuticals shares in Q4 2018, an estimated $12K.
Atwood & Palmer first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 6 quarters.
Atwood & Palmer's Aerie Pharmaceuticals position peaked at $14K in Q2 2018.
160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Atwood & Palmer's 13F filing for Q4 2018, filed 1 Feb 2019.